A Convenient Synthesis of CHF2O-Containing Pyrrolidines and Related Compounds — Prospective Building Blocks for Drug Discovery

Kostiantyn Levchenko; Ivan Virstiuk; Daria Menshykova; Nazariy Pokhodylo

doi:10.1055/s-0040-1720142

SynOpen, Inhaltsverzeichnis

CC BY 4.0 · SynOpen 2024; 08(04): 247-258
DOI: 10.1055/s-0040-1720142

paper

A Convenient Synthesis of CHF₂O-Containing Pyrrolidines and Related Compounds — Prospective Building Blocks for Drug Discovery

Kostiantyn Levchenko ∗

^aEnamine Ltd., 78 Winston Churchill Str., Kyiv 02094, Ukraine

^bDepartment of Organic Chemistry, Ivan Franko National University of Lviv, Kyryla i Mefodiya 6, 79005 Lviv, Ukraine

,

Ivan Virstiuk

^aEnamine Ltd., 78 Winston Churchill Str., Kyiv 02094, Ukraine

^bDepartment of Organic Chemistry, Ivan Franko National University of Lviv, Kyryla i Mefodiya 6, 79005 Lviv, Ukraine

,

Daria Menshykova

^aEnamine Ltd., 78 Winston Churchill Str., Kyiv 02094, Ukraine

^cDepartment of Organic Chemistry, Igor Sikorsky Kyiv Polytechnic Institute, Peremohy 37, 03056 Kyiv, Ukraine

,

Nazariy Pokhodylo

^bDepartment of Organic Chemistry, Ivan Franko National University of Lviv, Kyryla i Mefodiya 6, 79005 Lviv, Ukraine

› Institutsangaben

Abstract

Volltext

als PDF herunterladen Alle Artikel dieser Rubrik

Key words

fluorine - difluoromethoxy group - azetidine - pyrrolidine - proline - piperidine - building blocks

Fluorinated organic compounds are widely used in life sciences, agrochemicals, and materials science due to the unique properties of fluorine atoms.[1] [2] [3] Their strong electronegativity, small size, and capacity to form weak intermolecular bonds offer manifold benefits for customizing vital parameters of the target molecule. Fluorinated fragments are commonly used to adjust a compound’s physicochemical properties and enhance its biological properties, such as affinity or metabolic stability.[4–9] Among many other fluorine moieties, the CHF₂O group stands out for its ability to exhibit dynamic lipophilicity. It depends on the chemical environment and can be changed by simply rotating the bonds.[10] [11] The CHF₂O functional group possesses a hydrogen atom that can readily form an extra hydrogen bond within the binding site, thereby contributing to its distinct properties.[3] These properties have led to increasing interest in synthesizing compounds containing this group in the last decade.

Scheme 1 Proposed synthetic strategy

For aliphatic alcohols, only a few methods are available for their transformation into the CHF₂O group. These include difluoromethylation using 2,2-difluoro-2-(fluorosulfonyl)acetic acid,[12] conversion of formic acid ester,[13] O-difluoromethylation through an S-difluoromethyl sulfonium ylide,[14] [15] and desulfurative fluorination.[16,17] The introduction of the CHF₂O group was also achieved using (bromodifluoromethyl)trimethylsilane.[18] [19] [20] The first and last methods are preparative and scalable, but the difference in starting material price ($694.6/mol for (bromodifluoromethyl)trimethylsilane vs. $204.69/mol for 2,2-difluoro-2-(fluorosulfonyl)acetic acid are the current lowest prices at www.emolecules.com) makes the multigram synthesis of CHF₂O derivatives using 2,2-difluoro-2-(fluorosulfonyl)acetic acid more commercially attractive. In this work, we used this approach, the key stage of which was CuI-catalyzed alkylation with the FSO₂CF₂CO₂H N-protected functionalities of 4–6-membered saturated nitrogenous heterocyclic alcohols (Scheme [1]). The introduction of the CHF₂O-group via the reaction of FSO₂CF₂CO₂H with aliphatic alcohols was previously studied,[21] but it was only applied in a limited manner to heterocyclic derivatives. In addition, there is limited data on the choice of protecting groups that would tolerate the reaction conditions and be removed without leading to side products. Ways of incorporating additional functional groups, such as carboxyl to the second position of pyrrolidine, were also investigated, which made it possible to obtain derivatives with structures close to those of natural amino acids. Thus, in the current research, a mini-library of 21 compounds was synthesized by using the developed convenient methods.

Initially, commercially available nitrogen tert-butyloxycarbonyl (Boc) protected alcohols of saturated heterocycle derivatives (Scheme [2]) were tested under the previously elaborated reaction conditions. To compare protecting groups, we synthesized benzyloxycarbonyl (Cbz) protected derivatives. Notably, for several compounds, the replacement of the protecting groups has no significant influence. The reaction yields ranged from 39.6% for 3c and 41.6% for 3j to 65% for 3l. The initial attempt at difluoromethylating the Boc derivative of 2c yielded a maximum of 15%. Replacing the Boc protecting group with Cbz improved the yield significantly; however, it remained below the average yield for this reaction. It is hypothesized that this is due to steric effects. The final deprotection stage was conducted using acetyl chloride in a methanol solution for Boc derivatives or via catalytic hydrogenation in methanol at atmospheric pressure for Cbz derivatives. It is important to note that evaporation, particularly after the Boc deprotection process, must be carried out without overheating the reaction mass because the CHF₂O group is susceptible to hydrolysis to formate under acidic conditions. The catalytic hydrogenolysis of Cbz derivatives involved a two-step process: first, treatment with Raney nickel, followed by hydrogenolysis on palladium. This process was necessary to eliminate sulfur contamination in the starting material, which persisted even after two chromatographic purifications. The appearance of a distinct odor and slow or non-existent reaction during palladium-catalyzed hydrogenolysis confirmed the need for this step. After the reaction mass was treated with nickel, the reaction proceeded quickly under atmospheric pressure.

Scheme 2 Synthesis of compounds 4a–l. The yields of the last stage and over the two steps of difluoromethylation and deprotection (blue in parentheses) are given.

Alcohols of type 2a, 2b, 2d–f, and 2j–l can also be obtained from commercially available amino acids. We demonstrated this approach by synthesizing compound 4m (Scheme [3]). First, the available N-Boc-protected amino acid 1m was reduced with a borane disulfide complex in high yield. Then, by the reaction of alcohol, 2m with FSO₂CF₂CO₂H, a CHF₂O group was introduced in moderate yield. The final step was the Boc deprotection, which resulted in a high yield of 4m as the hydrochloride.

Scheme 3 Synthesis of compounds 4m

The possibility of designing multifunctional derivatives, such as CHF₂O-containing amino acids, was demonstrated by the preparation of compounds 4n–u. All possible optical isomers of 1-(tert-butoxycarbonyl)-4-(difluoromethoxy)pyrrolidine-2-carboxylic acid 4n–q and (2R,4S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-4-(difluoromethoxy)pyrrolidine-2-carboxylic acid 4r–u were obtained starting from commercially available methyl and benzyl esters of the 4-hydroxyproline isomers.

The synthesis of 4n–q utilized Boc-amino methyl esters 2n–q, prepared from available methyl ester 1n–q (Scheme [4]). Next, difluoromethylation and saponification steps proceeded in good or excellent yields. Finally, functionalization of the acid group on compound 4q was performed, producing chloromethyl ester 5 with a moderated yield. Compound 5 is suitable for further modification by nucleophilic substitution reactions.

Scheme 4 Synthesis of compounds 4n–q. The yields of the last stage and over the two steps of difluoromethylation and deprotection (blue in parentheses) are given.

Likewise to the aforementioned acids 4n–q, a set of optically pure fluorenylmethoxycarbonyl (Fmoc) protected amino acids 4r–u was prepared (Scheme [5]). It is noteworthy that the difluoromethylation step yields CHF₂O derivatives 3n–q in a range of 39.4% for 3u to 43.5% for 3r. Compared to the Boc and Cbz protecting groups, the Fmoc group was the least tolerant, leading to the lowest yields. The final step of the hydrogenolysis, as explained earlier, consisted of two stages: initial Raney nickel treatment followed by the hydrogenolysis stage, which gave high yields.

Scheme 5 Synthesis of compounds 4r–u. The yields of the last stage and over the two steps of difluoromethylation and deprotection (blue in parentheses) are given.

Thus, a mini-library of 21 compounds has been synthesized, comprising primary and secondary alcohol derivatives of azetidine, pyrrolidine (proline), piperidine, 2-azabicyclo[2.2.1]heptane, and 8-azabicyclo[3.2.1]octane. The protocol is suitable for multigram scale synthesis, useful for amino acid modification, and is tolerated by several protecting groups. We expect that the current work will be valuable for the use of CHF₂O cyclic amine derivatives in drug development projects.

Compounds 1j (CAS 3433-37-2), 1k (CAS 4606-65-9), 1l (CAS 6457-49-4), 1m (CAS 291775-59-2), 1r (CAS 153461-11-1), 1s (CAS 2140265-28-5), 1t (CAS 1864003-48-4), and 1u (CAS 62147-27-7) are commercially available. Solvents were purified according to standard procedures.

NMR spectra were recorded with Bruker Avance DRX and Varian Unity Plus spectrometers at 25 °C (for ¹H at 500 MHz and 400 MHz, for ¹³C and ¹⁹F at 126 MHz and 376 MHz, respectively). Tetramethylsilane (TMS) (for ¹H and ¹³C NMR) and CCl₃F (for ¹⁹F NMR) were used as internal standards. Mass spectra (ESI-MS) were recorded with Agilent 1290 Infinity II LC and Agilent 1260 Infinity II LC systems. The progress of reactions was monitored using TLC plates (silica gel 60 F254, Merck). Column chromatography was carried out on silica gel 60 (Merck, particle size 0.040–0.063 mm). Elemental analyses are correct within the limits of ±0.3%. Melting points are uncorrected. Compounds 1c,[30] 1p,[33] 2a,[22] 2b,[23], 2d,[24] 2e,[25] 2f,[26] 2g,[27] 2h,[28] 2i,[29] 2n,[31] 2o,[32] and 2q–4q [21] were previously characterized and obtained according to the procedures communicated elsewhere.

Synthesis of compounds 2c, 2j and 2k; General Procedure for Cbz-Protection

Potassium carbonate (1.5 equiv) was dissolved in water (2 mL/mmol) and a solution of the appropriate alcohol amine in THF (1.7 mL/mmol) was added. The resulting mixture was cooled to 0 °C in an ice bath and a solution of benzyl chloroformate (1.05 equiv) in THF (0.3 mL/mmol) was added dropwise at 0 °C. When the addition was complete, the resulting mixture was allowed to warm to r.t. and stirred overnight.

The reaction mixture was diluted with EtOAc and the organic layer was separated. The aqueous layer was extracted twice with EtOAc and the combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by flash chromatography to obtain Cbz-protected amino alcohol.

Benzyl 3-Hydroxy-3-methylazetidine-1-carboxylate (2c)

Purified by flash chromatography (hexane/MTBE, 2:1).

Yield: 75.5 g (70.3%); colorless thick oil.

¹H NMR (500 MHz, CDCl₃): δ = 7.41–7.27 (m, 4 H), 5.08 (d, J = 3.6 Hz, 2 H), 4.01–3.76 (m, 4 H), 2.92 (d, J = 3.8 Hz, 1 H), 1.49 (d, J = 3.5 Hz, 3 H).

¹³C NMR (126 MHz, CDCl₃): δ = 156.18, 135.98, 127.97, 127.56, 127.43, 68.00, 66.32, 62.98, 25.66.

MS (ES-API): m/z (%) = 178 (100) [M + 1 – CO₂]⁺, 91 (30) [C₆H₅CH₂]⁺.

Anal. Calcd for C₁₂H₁₅NO₃: C, 65.14; H, 6.83; N, 6.33. Found: C, 65.03; H, 6.91; N, 6.37.

Benzyl 2-(Hydroxymethyl)piperidine-1-carboxylate (2j)

Purified by flash chromatography (hexane/MTBE, 2:1).

Yield: 182 g (84.1%); colorless thick oil.

The NMR signal ranges of the compound obtained are in agreement with those previously characterized in the literature.[34]

¹H NMR (500 MHz, CDCl₃): δ = 7.40–7.28 (m, 4 H), 5.21–5.05 (m, 2 H), 4.35 (dtd, J = 8.6, 5.8, 2.3 Hz, 1 H), 4.03 (d, J = 13.1 Hz, 1 H), 3.86–3.76 (m, 1 H), 3.61 (dt, J = 11.1, 4.8 Hz, 1 H), 2.93 (s, 1 H), 2.39 (s, 1 H), 1.70 (d, J = 12.6 Hz, 1 H), 1.65–1.55 (m, 3 H), 1.55–1.35 (m, 2 H).

¹³C NMR (126 MHz, CDCl₃): δ = 158.51, 136.23, 127.96, 127.43, 127.26, 66.66, 60.81, 59.88, 52.38, 39.62, 24.69, 19.01, 13.68.

MS (ES-API): m/z (%) = 250 (15) [M + 1]⁺, 206 (100) [M + 1 – CO₂]⁺, 91 (50) [C₆H₅CH₂]⁺.

Anal. Calcd for C₁₄H₁₉NO₃: C, 67.45; H, 7.68; N, 5.62. Found: C, 67.35; H, 7.74; N, 5.78.

Benzyl 3-(Hydroxymethyl)piperidine-1-carboxylate (2k)

Purified by flash chromatography (hexane/MTBE, 2:1).

Yield: 179 g (82.7%); colorless thick oil.

The NMR signal ranges of the compound obtained are in agreement with those previously characterized in the literature.[35]

¹H NMR (500 MHz, CDCl₃): δ = 7.42–7.27 (m, 4 H), 5.11 (d, J = 7.8 Hz, 2 H), 4.09–3.70 (m, 2 H), 3.47 (q, J = 5.3 Hz, 2 H), 3.17–2.69 (m, 2 H), 2.31 (s, 1 H), 1.84–1.55 (m, 3 H), 1.45 (s, 1 H), 1.24 (s, 1 H).

¹³C NMR (126 MHz, CDCl₃): δ = 155.13, 136.33, 127.95, 127.43, 127.25, 66.54, 64.30, 63.92, 46.41, 44.31, 37.65, 26.40, 23.70.

MS (ES-API): m/z (%) = 250 (40) [M + 1]⁺, 206 (50%) [M + 1 – CO₂]⁺, 91 (100) [C₆H₅CH₂]⁺.

Anal. Calcd for C₁₄H₁₉NO₃: C, 67.45; H, 7.68; N, 5.62. Found: C, 67.35; H, 7.74; N, 5.78.

Synthesis of tert-Butyl (1R,3S,4S)-3-(Hydroxymethyl)-2-azabicyclo[2.2.1]heptane-2-carboxylate (2m)

Compound 1m (80 g, 331.55 mmol) was dissolved in THF (800 mL) and borane dimethyl sulfide complex (62.9 mL, 663.1 mmol, 2 equiv) was added dropwise at 20 °C under an argon atmosphere. After the addition was completed, the resulting mixture was stirred overnight.

Aq. K₂CO₃ solution (247 g in 350 mL of water) was carefully added dropwise to the reaction mixture. When the addition was complete, the resulting mixture was stirred for 30 minutes. The organic layer was separated and the aqueous layer was extracted with MTBE (2 × 600 mL). The combined organic layers were washed with water (600 mL) and brine (500 mL), dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (hexane/EtOAc, 2:1) to obtain compound 2m.

Yield: 72.9 g (95.8%); colorless thick oil.

¹H NMR (500 MHz, CDCl₃): δ = 4.41 (s, 1 H), 4.15–4.01 (m, 1 H), 3.72–3.22 (m, 3 H), 2.36 (d, J = 80.9 Hz, 1 H), 1.75–1.62 (m, 2 H), 1.62–1.52 (m, 2 H), 1.44 (s, 9 H), 1.23 (dd, J = 8.5, 6.0 Hz, 1 H).

¹³C NMR (126 MHz, CDCl₃): δ = 156.80, 79.69, 66.71, 66.10, 57.40, 39.18, 35.17, 29.23, 27.95, 27.40, 13.66.

MS (ES-API): m/z (%) = 172 (100) [M + 1 – 70]⁺.

Anal. Calcd for C₁₂H₁₉NO₄: C, 59.73; H, 7.94; N, 5.81. Found: C, 59.81; H, 7.79; N, 5.99.

Synthesis of (2R,4S)-1-tert-Butyl 2-Methyl 4-hydroxypyrrolidine-1,2-dicarboxylate (2p)

Compound 1p (15 g, 82.6 mmol) was suspended in DCM (150 mL) and TEA (24.17 mL, 173.4 mmol, 2.1 equiv) was added. The resulting mixture was stirred for 15 minutes, and a solution of di-tert-butyl dicarbonate (18.38 g, 84.2 mmol, 1.02 equiv) in DCM (35 mL) was added dropwise. When the addition was complete, the resulting mixture was stirred overnight.

Water (150 mL) was added to the reaction mixture, and the organic layer was separated. The aqueous layer was extracted with DCM (50 mL), and the combined organic layers were dried over Na₂SO₄, filtered, and concentrated in vacuo to obtain compound 2p.

Yield 18.5 g (91%); colorless thick oil.

The NMR signal ranges of the compound obtained are in agreement with those previously characterized in the literature.[36]

¹H NMR (500 MHz, CDCl₃): δ = 4.45–4.38 (m, 1 H), 4.38–4.29 (m, 1 H), 3.67 (d, J = 2.9 Hz, 3 H), 3.58–3.28 (m, 3 H), 2.24 (ddd, J = 20.6, 11.1, 6.2 Hz, 1 H), 1.98 (ddd, J = 13.2, 7.9, 4.8 Hz, 1 H), 1.37 (d, J = 25.2 Hz, 10 H).

¹³C NMR (126 MHz, CDCl₃): δ = 173.19, 172.97, 158.52, 154.05, 153.49, 79.84, 69.32, 68.59, 57.44, 57.00, 54.16, 54.08, 51.68, 51.49, 38.51, 37.85, 30.58, 27.82, 27.68, 27.17.

MS (ES-API): m/z (%) = 146 (100) [M + 1 – Boc]⁺, 146 (100) [M + 1 – t-Bu]⁺.

Anal. Calcd for C₁₁H₁₉NO₅: C, 53.87; H, 7.81; N, 5.71. Found: C, 53.99; H, 7.75; N, 5.90.

Synthesis of compounds 2r–u; General Procedure for Fmoc Protection

The corresponding compound 1r–u dissolved in water (3.5 mL/mmol) and sodium bicarbonate (4 equiv) was added. The resulting mixture was stirred for 20 min then THF (3 mL/mmol) was added. The resulting mixture was cooled to 0 °C in an ice bath, and a solution of fluorenylmethyloxycarbonyl chloride (1.15 equiv) in THF (0.5 mL/mmol) was added dropwise at 0 °C. When the addition was complete, the resulting mixture was allowed to warm to r.t. and stirred overnight.

The reaction mixture was extracted twice with EtOAc and the combined organic layers were washed with water and brine, dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by flash chromatography to obtain the appropriate compound.

(2R,4S)-1-((9H-Fluoren-9-yl)methyl) 2-Benzyl 4-Hydroxypyrrolidine-1,2-dicarboxylate (2r)

Purified by flash chromatography (hexane/EtOAc, 2:1).

Yield: 26 g (60%); light-yellow solid; mp 36 °C.

¹H NMR (400 MHz, CDCl₃): δ = 7.93–7.68 (m, 2 H), 7.63–7.45 (m, 2 H), 7.42–7.15 (m, 9 H), 5.25–4.98 (m, 2 H), 4.64–4.18 (m, 4 H), 3.79–3.43 (m, 2 H), 2.48–2.19 (m, 1 H), 2.09 (dt, J = 13.0, 6.2 Hz, 1 H), 1.80 (s, 1 H).

¹³C NMR (126 MHz, CDCl₃): δ = 215.34, 171.73, 158.52, 143.61, 143.51, 140.77, 140.74, 134.81, 128.02, 127.88, 127.76, 127.58, 127.17, 127.10, 126.55, 124.67, 124.59, 124.44, 119.44, 119.38, 69.62, 68.80, 67.24, 67.08, 66.49, 66.41, 59.93, 57.54, 57.24, 54.80, 54.13, 46.68, 46.61, 38.82, 37.86.

MS (ES-API): m/z (100) = 444 [M + 1]⁺.

Anal. Calcd for C₂₇H₂₅NO₅: C, 73.12; H, 5.68; N, 3.16. Found: C, 73.05; H, 5.79; N, 3.21.

(2R,4R)-1-((9H-Fluoren-9-yl)methyl) 2-Benzyl 4-hydroxypyrrolidine-1,2-dicarboxylate (2s)

Purified by flash chromatography (hexane/EtOAc, 2:1).

Yield: 42 g (84%); white solid; mp 36 °C.

¹H NMR (500 MHz, DMSO-d ₆): δ = 7.88 (dd, J = 14.1, 7.6 Hz, 2 H), 7.61 (dd, J = 38.3, 7.5 Hz, 2 H), 7.50–7.20 (m, 10 H), 5.22–4.97 (m, 3 H), 4.48–4.06 (m, 5 H), 3.53 (dd, J = 11.1, 5.2 Hz, 1 H), 3.23 (td, J = 11.4, 3.1 Hz, 1 H), 2.33 (td, J = 8.2, 4.2 Hz, 1 H), 1.97–1.88 (m, 1 H).

¹³C NMR (126 MHz, DMSO-d ₆): δ = 171.52, 171.31, 170.26, 158.52, 154.02, 153.74, 143.80, 143.75, 143.64, 140.71, 140.69, 140.60, 136.04, 135.91, 128.27, 127.84, 127.79, 127.62, 127.56, 127.53, 127.41, 127.07, 127.03, 126.98, 125.02, 124.95, 120.09, 120.02, 68.48, 67.55, 66.59, 65.82, 65.66, 59.70, 57.67, 57.30, 54.55, 53.99, 46.56, 38.67, 37.64, 20.70, 14.03.

MS (ES-API): m/z (100) = 444 [M + 1]⁺.

Anal. Calcd for C₂₇H₂₅NO₅: C, 73.12; H, 5.68; N, 3.16. Found: C, 73.23; H, 5.51; N, 3.03.

(2S,4S)-1-((9H-Fluoren-9-yl)methyl) 2-Benzyl 4-hydroxypyrrolidine-1,2-dicarboxylate (2t)

Purified by flash chromatography (hexane/EtOAc, 2:1).

Yield: 48.4 g (69%); light-yellow thick oil.

The NMR signal ranges of the compound obtained are in agreement with those previously characterized in the literature.[37]

¹H NMR (400 MHz, CDCl₃): δ = 7.75 (t, J = 7.2 Hz, 2 H), 7.64–7.45 (m, 2 H), 7.45–7.10 (m, 9 H), 5.33–5.03 (m, 3 H), 4.56–4.19 (m, 5 H), 3.82–3.54 (m, 2 H), 3.45–2.68 (m, 1 H), 2.34 (tdd, J = 14.2, 9.7, 4.6 Hz, 1 H), 2.14 (t, J = 14.5 Hz, 1 H).

¹³C NMR (151 MHz, CDCl₃): δ = 174.20, 173.83, 154.96, 154.45, 144.15, 143.97, 143.74, 143.55, 141.34, 141.31, 141.28, 141.21, 135.20, 135.04, 128.60, 128.56, 128.51, 128.42, 128.39, 128.20, 127.76, 127.73, 127.66, 127.11, 127.09, 127.02, 125.13, 125.08, 125.02, 124.90, 120.00, 119.95, 71.10, 70.00, 67.70, 67.67, 67.55, 67.46, 60.41, 58.30, 57.89, 56.06, 55.68, 53.47, 47.17, 47.15, 38.94, 37.82, 21.06, 14.22.

MS (ES-API): m/z (%) = 444 (100) [M + 1]⁺.

Anal. Calcd for C₂₇H₂₅NO₅: C, 73.12; H, 5.68; N, 3.16. Found: C, 73.30; H, 5.75; N, 3.23.

(2S,4R)-1-((9H-Fluoren-9-yl)methyl) 2-Benzyl 4-hydroxypyrrolidine-1,2-dicarboxylate (2u)

Purified by flash chromatography (hexane/EtOAc, 2:1).

Yield: 49.7 g (64%); yellow thick oil.

The NMR signal ranges of the compound obtained are in agreement with those previously characterized in the literature.[37]

¹H NMR (500 MHz, CDCl₃): δ = 7.85–7.65 (m, 2 H), 7.65–7.47 (m, 2 H), 7.45–7.19 (m, 9 H), 5.25–4.97 (m, 2 H), 4.71–4.38 (m, 3 H), 4.38–4.18 (m, 2 H), 3.80–3.48 (m, 2 H), 2.44–2.26 (m, 1 H), 2.10 (ddd, J = 12.4, 7.1, 4.4 Hz, 1 H).

¹³C NMR (151 MHz, CDCl₃): δ = 172.33, 171.23, 155.01, 154.71, 144.12, 144.02, 143.79, 143.53, 141.31, 141.27, 141.16, 135.52, 135.32, 128.54, 128.52, 128.39, 128.27, 128.09, 127.69, 127.67, 127.61, 127.08, 127.06, 127.03, 125.18, 125.12, 125.10, 124.95, 119.95, 119.90, 119.88, 70.10, 69.27, 67.74, 67.59, 66.98, 66.91, 58.06, 57.75, 55.30, 54.63, 53.43, 47.17, 47.10, 39.31, 38.35.

MS (ES-API): m/z (%) = 444 (100) [M + 1]⁺.

Anal. Calcd for C₂₇H₂₅NO₅: C, 73.12; H, 5.68; N, 3.16. Found: C, 73.30; H, 5.75; N, 3.23.

Synthesis of Compounds 3a–u; General Procedure for Difluoromethylation

Protected amino alcohol was dissolved in MeCN (2.5 mL/mmol), and copper(I) iodide (0.2 equiv) was added. The resulting mixture was heated to 45 °C, and a solution of 2,2-difluoro-2-(fluorosulfonyl)acetic acid in MeCN (1 mL/mmol) was slowly added dropwise, maintaining the internal temperature below 50 °C. When the addition was complete, the reaction mixture was heated at 45 °C for 30 minutes.

The reaction mixture was concentrated in vacuo and the residue was diluted with EtOAc/petroleum ether (1:1). The resulting mixture was filtered through a short SiO₂ pad, and the pad was washed with an additional amount of EtOAc/petroleum ether (1:1). The filtrate was concentrated in vacuo and the residue was purified by flash chromatography.

tert-Butyl 3-((Difluoromethoxy)methyl)azetidine-1-carboxylate (3a)

Purified by flash chromatography (hexane/EtOAc, 5:1).

Yield: 84 g (53%); colorless oil.

¹H NMR (400 MHz, CDCl₃): δ = 6.19 (td, J = 74.1, 2.3 Hz, 1 H), 4.04–3.90 (m, 4 H), 3.66 (ddd, J = 8.1, 5.4, 2.1 Hz, 2 H), 2.79 (hept, J = 7.0, 6.5 Hz, 1 H), 1.40 (s, 9 H).

¹³C NMR (126 MHz, CDCl₃): δ = 155.73 (CO), 117.22, 115.16 (t, ¹ J _C–F = 261.6 Hz, CHF₂), 78.98 (2 × CH₂N), 63.77 (t, ³ J _C–F = 5.7 Hz, CH₂O), 27.82 (3 × СH₃), 27.40.

¹⁹F NMR (376 MHz, CDCl₃): δ = –85.01.

MS (ES-API): m/z (%) = 182 (100) [M + 1 – tBu]⁺.

Anal. Calcd for C₁₀H₁₇F₂NO₃: C, 50.63; H, 7.22; N, 5.90. Found: C, 50.74; H, 7.31; N, 5.99.

tert-Butyl 2-((Difluoromethoxy)methyl)azetidine-1-carboxylate (3b)

Purified by flash chromatography (hexane/EtOAc, 5:1).

Yield: 44 g (43%); colorless oil.

¹H NMR (400 MHz, CDCl₃): δ = 6.22 (t, J = 74.7 Hz, 1 H), 4.32 (q, J = 4.3 Hz, 1 H), 4.12 (dd, J = 10.9, 4.6 Hz, 1 H), 3.89 (dd, J = 10.8, 2.9 Hz, 1 H), 3.78 (ddd, J = 9.7, 6.8, 3.1 Hz, 2 H), 2.34–2.00 (m, 2 H), 1.40 (d, J = 1.5 Hz, 9 H).

¹³C NMR (151 MHz, CDCl₃): δ = 155.93 (CO), 116.08 (t, ¹ J _C–F = 262.8 Hz, CHF₂), 79.63, 63.74, 59.79, 46.54, 28.31 (3 × CH₃), 18.60.

¹⁹F NMR (376 MHz, CDCl₃): δ = –84.56.

MS (ES-API): m/z (%) = 162 (100), 182 (50) [M + 1 – tBu]⁺.

Anal. Calcd for C₁₀H₁₇F₂NO₃: C, 50.63; H, 7.22; N, 5.90. Found: C, 50.59; H, 7.17; N, 5.94.

Benzyl 3-(Difluoromethoxy)-3-methylazetidine-1-carboxylate (3c)

Purified by flash chromatography (hexane/EtOAc, 7:1).

Yield: 39.6 g (40%); light-yellow oil.

¹H NMR (500 MHz, CDCl₃): δ = 7.40–7.28 (m, 4 H), 6.25 (td, J = 74.4, 3.3 Hz, 1 H), 5.11 (d, J = 3.0 Hz, 2 H), 4.16 (d, J = 9.5 Hz, 2 H), 3.89 (d, J = 9.4 Hz, 2 H), 1.66 (s, 3 H).

¹³C NMR (126 MHz, CDCl₃): δ = 155.91 (CO), 135.83 (C_Ar-1), 128.00 (2 × CH_Ar), 127.65 (CH_Ar-4), 127.52 (2 × CH_Ar), 115.15 (t, ¹ J _C–F = 258.8 Hz, CHF₂), 73.18 (t, ³ J _C–F = 2.4 Hz, C-O), 66.46 (2 × CH₂N), 60.98 (CH₂O), 23.36 (CH₃).

¹⁹F NMR (376 MHz, CDCl₃): δ = –80.28 (d, J = 27.3 Hz).

MS (ES-API): m/z (%) = 228 (100) [M + 1 – 44]⁺.

Anal. Calcd for C₁₃H₁₅F₂NO₃: C, 57.56; H, 5.57; N, 5.16. Found: C, 57.71; H, 5.50; N, 5.21.

(S)-tert-Butyl 2-((Difluoromethoxy)methyl)pyrrolidine-1-carboxylate (3d)

Purified by flash chromatography (hexane/EtOAc, 5:1).

Yield: 47.1 g (50.3%); colorless oil.

¹H NMR (400 MHz, CDCl₃): δ = 6.17 (t, J = 74.9 Hz, 1 H), 3.94 (d, J = 9.8 Hz, 2 H), 3.88 (s, 1 H), 3.32 (s, 2 H), 2.07–1.71 (m, 4 H), 1.44 (s, 9 H).

¹³C NMR (151 MHz, CDCl₃): δ = 154.49 and 154.19 (CO), 116.17 (t, ¹ J _C–F = 258.7 Hz) and 115.77 (t, ¹ J _C–F = 260.9 Hz) (CHF₂), 79.59 and 79.34, 63.97 and 63.71, 55.81, 46.85 and 46.43, 28.32 (3xCH₃), 28.54 and 27.70, 23.62 and 22.75.

¹⁹F NMR (376 MHz, CDCl₃): δ = –83.60 (d, ² J = 12.5 Hz), –84.43.

MS (ES-API): m/z (%) = 252 (100) [M + 1]⁺.

Anal. Calcd for C₁₁H₁₉F₂NO₃: C, 52.58; H, 7.62; N, 5.57. Found: C, 52.50; H, 7.73; N, 5.51.

(R)-tert-Butyl 2-((Difluoromethoxy)methyl)pyrrolidine-1-carboxylate (3e)

Purified by flash chromatography (hexane/EtOAc, 5:1).

Yield: 47.15 g (63%); colorless oil.

¹H NMR (400 MHz, CDCl₃): δ = 6.16 (t, J = 74.9 Hz, 1 H), 4.03–3.90 (m, 1 H), 3.87 (s, 1 H), 3.44–3.22 (m, 2 H), 2.08–1.71 (m, 4 H), 1.43 (s, 9 H).

¹³C NMR (151 MHz, CDCl₃): δ = 154.49 and 154.20, 116.17 (t, J = 259.3 Hz) and 115.78 (t, J = 261.6 Hz, CHF₂), 79.60 and 79.35, 63.98 and 63.71, 55.81 and 53.33, 46.86 and 46.44, 28.33 (3 × CH₃), 28.55 and 27.70, 23.63 and 22.76.

¹⁹F NMR (376 MHz, CDCl₃): δ = –83.63 (d, ² J = 12.1 Hz), –84.45.

MS (ES-API): m/z (%) = 252 (100) [M + 1]⁺.

Anal. Calcd for C₁₁H₁₉F₂NO₃: C, 52.58; H, 7.62; N, 5.57. Found: C, 52.47; H, 7.59; N, 5.55.

(1R,3R,5S)-tert-Butyl 3-(Difluoromethoxy)-8-azabicyclo[3.2.1]octane-8-carboxylate (3f)

Purified by flash chromatography (hexane/EtOAc, 4:1).

Yield: 63.9 g (46%); white solid; mp 38 °C.

¹H NMR (500 MHz, CDCl₃): δ = 6.18 (td, J = 75.0, 3.2 Hz, 1 H), 4.43 (t, J = 4.7 Hz, 1 H), 4.16 (d, J = 42.6 Hz, 2 H), 2.06 (d, J = 6.5 Hz, 4 H), 1.92 (d, J = 7.2 Hz, 2 H), 1.83 (d, J = 14.8 Hz, 2 H), 1.44 (d, J = 3.1 Hz, 9 H).

¹³C NMR (126 MHz, CDCl₃): δ = 152.76 (CO), 116.04 (t, ¹ J _C–F = 258.0 Hz, CHF₂), 78.77, 69.14 (t, ³ J _C–F = 4.2 Hz), 52.16, 51.36, 36.00, 35.22, 27.94 (3 × CH₃), 27.47, 26.80.

¹⁹F NMR (376 MHz, CDCl₃): δ = –82.1.

MS (ES-API): m/z (%) = 178 (100) [M + 1 – Boc]⁺, 222 (25) [M + 1 – tBu]⁺.

Anal. Calcd for C₁₃H₂₁F₂NO₃: C, 56.31; H, 7.63; N, 5.05. Found: C, 56.21; H, 7.75; N, 5.14.

(S)-tert-Butyl 3-(Difluoromethoxy)piperidine-1-carboxylate (3g)

Purified by flash chromatography (hexane/EtOAc, 7:1).

Yield: 45.92 g (61.3%); colorless oil.

¹H NMR (500 MHz, CDCl₃): δ = 6.45–6.01 (m, 1 H), 4.21–4.06 (m, 1 H), 4.03–3.62 (m, 1 H), 3.54 (s, 1 H), 3.15 (s, 2 H), 1.93 (s, 1 H), 1.76 (s, 1 H), 1.70–1.59 (m, 1 H), 1.44 (d, J = 1.4 Hz, 9 H).

¹³C NMR (151 MHz, CDCl₃): δ = 154.72 (CO), 115.94 (t, ¹ J _C–F = 259.9 Hz, CHF₂), 79.77, 69.04, 49.96–46.85 (m), 44.58–42.67 (m), 30.79, 28.29 (3 × CH₃), 23.17–21.64 (m).

¹⁹F NMR (376 MHz, CDCl₃): δ = –81.95, –82.22.

MS (ES-API): m/z (%) = 84 (100) [M + 1 – Boc – CHF₂O]⁺, 152 (15) [M + 1 – Boc]⁺.

Anal. Calcd for C₁₁H₁₉F₂NO₃: C, 52.58; H, 7.62; N, 5.57. Found: C, 52.63; H, 7.71; N, 5.55.

(R)-tert-Butyl 3-(Difluoromethoxy)piperidine-1-carboxylate (3h)

Purified by flash chromatography (hexane/EtOAc, 7:1).

Yield: 52.27 g (59.5%); colorless thick oil.

¹H NMR (500 MHz, CDCl₃): δ = 6.23 (td, J = 74.9, 1.5 Hz, 1 H), 4.12 (tt, J = 7.8, 3.7 Hz, 1 H), 3.99–3.61 (m, 1 H), 3.52 (s, 1 H), 3.14 (s, 2 H), 1.91 (d, J = 11.2 Hz, 1 H), 1.83–1.69 (m, 1 H), 1.64 (d, J = 10.2 Hz, 1 H), 1.43 (d, J = 1.6 Hz, 9 H).

¹³C NMR (151 MHz, CDCl₃): δ = 154.70 (CO), 115.95 (t, ¹ J _C–F = 259.9 Hz, CHF₂), 79.73, 69.04, 49.96–46.85 (m), 44.58–42.67 (m), 30.76, 28.26 (3 × CH₃), 23.17–21.64 (m).

¹⁹F NMR (376 MHz, CDCl₃): δ = –81.97, –82.20.

MS (ES-API): m/z (%) = 84 (100) [M + 1 – Boc – CHF₂O]⁺, 152 (15) [M + 1 – Boc]⁺.

Anal. Calcd for C₁₁H₁₉F₂NO₃: C, 52.58; H, 7.62; N, 5.57. Found: C, 52.71; H, 7.55; N, 5.48.

tert-Butyl 4-(Difluoromethoxy)piperidine-1-carboxylate (3i)

Purified by flash chromatography (hexane/EtOAc, 7:1).

Yield: 68.42 g (54.8%); light-yellow thick oil.

¹H NMR (500 MHz, CDCl₃): δ = 6.25 (t, J = 74.8 Hz, 1 H), 4.34 (dt, J = 7.9, 4.0 Hz, 1 H), 3.70 (dq, J = 9.8, 3.4, 2.9 Hz, 2 H), 3.23 (ddd, J = 13.5, 8.4, 3.7 Hz, 2 H), 1.84 (dq, J = 10.3, 3.3 Hz, 2 H), 1.67 (ddt, J = 13.0, 8.7, 4.1 Hz, 2 H), 1.45 (s, 10 H).

¹³C NMR (151 MHz, CDCl₃): δ = 154.70 (CO), 116.08 (t, ¹ J _C–F = 259.6 Hz, CHF₂), 79.74, 70.60 (t, ³ J _C–F = 4.2 Hz), 40.63 (2 × CH₂N), 31.82 (2 × CH₂), 28.38 (3 × CH₃).

¹⁹F NMR (376 MHz, CDCl₃): δ = –81.70.

MS (ES-API): m/z (%) = 84 (100) [M + 1 – Boc – CHF₂O]⁺, 152 (50) [M + 1 – Boc]⁺.

Anal. Calcd for C₁₁H₁₉F₂NO₃: C, 52.58; H, 7.62; N, 5.57. Found: C, 52.42; H, 7.48; N, 5.48.

Benzyl 2-((Difluoromethoxy)methyl)piperidine-1-carboxylate (3j)

Purified by flash chromatography (hexane/EtOAc, 8:1).

Yield: 90 g (42%); light-yellow oil.

¹H NMR (500 MHz, CDCl₃): δ = 7.45–7.28 (m, 6 H), 6.16 (t, J = 74.3 Hz, 1 H), 5.14 (q, J = 12.5 Hz, 2 H), 4.61–4.44 (m, 1 H), 4.11 (d, J = 13.7 Hz, 1 H), 3.99 (dd, J = 10.0, 7.6 Hz, 1 H), 3.88 (dd, J = 10.0, 7.2 Hz, 1 H), 2.86 (t, J = 13.0 Hz, 1 H), 1.76 (d, J = 13.5 Hz, 1 H), 1.70–1.58 (m, 3 H), 1.59–1.36 (m, 2 H).

¹³C NMR (151 MHz, CDCl₃): δ = 155.66 (CO), 136.77, 128.43 (2 × CH_Ph), 127.92, 127.80 (2 × CH_Ph), 115.71 (t, ¹ J _C–F = 261.4 Hz, CHF₂), 67.12, 60.64 (t, ¹ J _C–F = 5.0 Hz, CH₂O), 49.27, 39.90, 25.04, 24.99, 19.06.

¹⁹F NMR (376 MHz, CDCl₃): δ = –85.08.

MS (ES-API): m/z (%) = 91 (100) [C₇H₇]⁺, 300 (15) [M + 1]⁺.

Anal. Calcd for C₁₅H₁₉F₂NO₃: C, 60.19; H, 6.40; N, 4.68. Found: C, 60.04; H, 6.29; N, 4.77.

Benzyl 3-((Difluoromethoxy)methyl)piperidine-1-carboxylate (3k)

Purified by flash chromatography (hexane/EtOAc, 6:1).

Yield: 85 g (60.5%); light-yellow oil.

¹H NMR (500 MHz, CDCl₃): δ = 7.42–7.27 (m, 5 H), 6.18 (t, J = 74.6 Hz, 1 H), 5.13 (d, J = 3.8 Hz, 2 H), 3.98 (dt, J = 13.5, 4.3 Hz, 2 H), 3.71 (tt, J = 17.2, 7.8 Hz, 2 H), 3.14–2.55 (m, 2 H), 1.96–1.76 (m, 2 H), 1.76–1.58 (m, 1 H), 1.49 (s, 1 H), 1.35–1.17 (m, 1 H).

¹³C NMR (151 MHz, CDCl₃): δ = 155.30 (CO), 136.86, 128.45 (2 × CH_Ph), 127.93, 127.81 (2 × CH_Ph), 115.84 (t, ¹ J _C–F = 260.7 Hz, CHF₂), 67.03, 65.02, 46.76, 44.50, 35.54, 26.90, 24.22.

¹⁹F NMR (376 MHz, CDCl₃): δ = –85.03.

MS (ES-API): m/z (%) = 91 (100) [C₇H₇]⁺, 236 (92) [M + 1 – 64]⁺.

Anal. Calcd for C₁₅H₁₉F₂NO₃: C, 60.19; H, 6.40; N, 4.68. Found: C, 60.28; H, 6.35; N, 4.54.

Benzyl 4-((Difluoromethoxy)methyl)piperidine-1-carboxylate (3l)

Purified by flash chromatography (hexane/EtOAc, 6:1).

Yield: 75 g (65%); colorless oil.

¹H NMR (500 MHz, CDCl₃): δ = 7.43–7.29 (m, 5 H), 6.19 (t, J = 74.7 Hz, 1 H), 5.13 (s, 2 H), 4.22 (s, 2 H), 3.69 (d, J = 6.4 Hz, 2 H), 2.79 (s, 2 H), 1.91–1.59 (m, 3 H), 1.21 (q, J = 13.6, 12.6 Hz, 2 H).

¹³C NMR (151 MHz, CDCl₃): δ = 155.21 (CO), 136.84, 128.46 (2 × CH_Ph), 127.94, 127.84 (2 × CH_Ph), 115.91 (t, ¹ J _C–F = 260.4 Hz, CHF₂), 67.32 (t, J = 5.2 Hz, CH₂O), 67.03, 43.64 (2 × CH₂), 35.82 (2 × CH₂), 28.40.

¹⁹F NMR (376 MHz, CDCl₃): δ = –84.69.

MS (ES-API): m/z (%) = 91 (100) [C₇H₇]⁺, 236 (92) [M + 1 – 64]⁺.

Anal. Calcd for C₁₅H₁₉F₂NO₃: C, 60.19; H, 6.40; N, 4.68. Found: C, 60.09; H, 6.54; N, 4.81.

(1R,3S,4S)-tert-Butyl 3-((Difluoromethoxy)methyl)-2-azabicyclo[2.2.1]heptane-2-carboxylate (3m)

Purified by flash chromatography (hexane/EtOAc, 5:1).

Yield: 26.52 g (49%); colorless oil.

¹H NMR (500 MHz, CDCl₃): δ = 6.18 (t, J = 74.9 Hz, 1 H), 4.17–3.94 (m, 2 H), 3.54 (t, J = 9.5 Hz, 1 H), 3.50–3.40 (m, 1 H), 2.53 (d, J = 4.2 Hz, 1 H), 1.79–1.53 (m, 5 H), 1.44 (s, 11 H), 1.39 (dd, J = 11.7, 7.1 Hz, 1 H), 1.25 (d, J = 10.2 Hz, 1 H).

¹³C NMR (151 MHz, CDCL₃): δ = 155.14 and 154.48 (CO), 116.07 (t, ¹ J _C–F = 259.6 Hz) and 115.73 (t, ¹ J _C–F = 260.9 Hz) (CHF₂), 79.77 and 79.51, 63.05 and 62.90, 62.44 and 62.21, 57.57 and 56.64, 39.34 and 38.72, 34.56 and 33.79, 30.22 and 29.71, 28.53, 28.45 and 28.37, 27.54, 27.37.

¹⁹F NMR (376 MHz, CDCl₃): δ = –83.78, –84.37.

MS (ES-API): m/z (%) = 154 (100) [M + 1 – tBu – CHF₂ – OH]⁺, 222 (15) [M + 1 – tBu]⁺.

Anal. Calcd for C₁₃H₂₁F₂NO₃: C, 56.31; H, 7.63; N, 5.05. Found: C, 56.24; H, 7.71; N, 5.19.

(2R,4R)-1-tert-Butyl 2-Methyl 4-(Difluoromethoxy)pyrrolidine-1,2-dicarboxylate (3n)

Purified by flash chromatography (hexane/EtOAc, 3:1).

Yield: 36.6 g (60%); white solid; mp 27 °C.

¹H NMR (500 MHz, CDCl₃): δ = 6.18 (t, J = 73.3 Hz, 1 H), 4.79 (ddd, J = 14.0, 6.5, 3.2 Hz, 1 H), 4.37 (ddd, J = 54.9, 9.2, 3.8 Hz, 1 H), 3.72 (s, 4 H), 3.56 (ddd, J = 16.0, 11.8, 3.4 Hz, 1 H), 2.46 (dddd, J = 26.1, 14.4, 9.2, 5.7 Hz, 1 H), 2.27 (dt, J = 13.9, 3.8 Hz, 1 H), 1.43 (d, J = 26.2 Hz, 9 H).

¹³C NMR (151 MHz, CDCl₃): δ = 172.33 and 172.00, 153.95 and 153.42, 115.45 (t, ¹ J _C–F = 262.1 Hz, CHF₂), 80.43 and 80.38, 71.75 and 70.81, 57.40 and 57.01, 52.41 and 52.26, 52.10 and 51.86, 36.94 and 36.11, 28.32 and 28.19 (3 × CH₃).

¹⁹F NMR (376 MHz, CDCl₃): δ = –83.19, –83.62, –83.62, –83.80, –83.83, –84.22, –84.26.

MS (ES-API): m/z (%) = 196 (100) [M + 1 – Boc]⁺.

Anal. Calcd for C₁₂H₁₉F₂NO₅: C, 48.81; H, 6.49; N, 4.74. Found: C, 48.91; H, 6.35; N, 4.82.

(2S,4S)-1-tert-Butyl 2-Methyl 4-(Difluoromethoxy)pyrrolidine-1,2-dicarboxylate (3o)

Purified by flash chromatography (hexane/EtOAc, 3:1).

Yield: 38.5 g (54%); colorless thick oil.

¹H NMR (500 MHz, CDCl₃): δ = 6.18 (t, J = 73.3 Hz, 1 H), 4.79 (tt, J = 9.6, 4.9 Hz, 1 H), 4.37 (ddd, J = 55.2, 9.1, 3.8 Hz, 1 H), 3.72 (s, 4 H), 3.56 (ddd, J = 16.1, 12.2, 3.4 Hz, 1 H), 2.46 (dtd, J = 26.6, 11.6, 8.9, 5.7 Hz, 1 H), 2.27 (dt, J = 13.9, 3.9 Hz, 1 H), 1.42 (d, J = 26.2 Hz, 9 H).

¹³C NMR (101 MHz, CDCl₃): δ = 172.35 and 172.02, 153.98 and 153.44, 115.47 (t, ¹ J _C–F = 262.3 Hz, CHF₂), 80.46 and 80.41, 71.76 (t, J = 5.3 Hz) and 70.81 (t, ³ J _C–F = 5.2 Hz) (CH₂O), 57.41 and 57.03, 52.44 and 52.29, 52.13 and 51.88, 36.96 and 36.14, 28.33 and 28.21 (3 × CH₃).

¹⁹F NMR (376 MHz, CDCl₃): δ = –83.18, –83.19, –83.61, –83.62, –83.79, –83.82, –84.21, –84.25.

MS (ES-API): m/z (%) = 196 (100) [M + 1 – Boc]⁺.

Anal. Calcd for C₁₂H₁₉F₂NO₅: C, 48.81; H, 6.49; N, 4.74. Found: C, 48.99; H, 6.59; N, 4.52.

(2R,4S)-1-tert-Butyl 2-Methyl 4-(Difluoromethoxy)pyrrolidine-1,2-dicarboxylate (3p)

Purified by flash chromatography (hexane/EtOAc 3:1).

Yield: 12 g (53.9%); white solid; mp 68 °C.

¹H NMR (500 MHz, CDCl₃): δ = 6.21 (t, J = 73.5 Hz, 1 H), 4.83 (p, J = 4.8 Hz, 1 H), 4.37 (dt, J = 36.4, 7.4 Hz, 1 H), 3.77–3.49 (m, 5 H), 2.50–2.31 (m, 1 H), 2.16 (ddd, J = 13.2, 7.0, 5.2 Hz, 1 H), 1.42 (d, J = 23.2 Hz, 9 H).

¹³C NMR (101 MHz, CDCl₃): δ = 173.06 and 172.88, 153.99 and 153.41, 115.63 (t, ¹ J _C–F = 261.9 Hz, CHF₂), 80.53, 71.78 (t, J = 5.1 Hz) and 71.78 (t, J = 5.1 Hz) (CH₂O), 57.61 and 57.17, 52.33 and 52.14, 37.23 and 36.24, 28.31 and 28.19 (3 × CH₃).

¹⁹F NMR (376 MHz, CDCl₃): δ = –82.95, –83.37, –83.49, –83.92.

MS (ES-API): m/z (%) = 196 (100) [M + 1 – Boc]⁺.

Anal. Calcd for C₁₂H₁₉F₂NO₅: C, 48.81; H, 6.49; N, 4.74. Found: C, 48.91; H, 6.35; N, 4.82.

(2R,4S)-1-((9H-Fluoren-9-yl)methyl) 2-Benzyl 4-(Difluoromethoxy)pyrrolidine-1,2-dicarboxylate (3r)

Purified by flash chromatography (hexane/EtOAc, 4:1).

Yield: 12.6 g (43%); light-yellow thick oil.

¹H NMR (400 MHz, CDCl₃): δ = 7.75 (t, J = 7.0 Hz, 2 H), 7.65–7.45 (m, 2 H), 7.45–7.17 (m, 8 H), 6.22 (td, J = 73.2, 7.1 Hz, 1 H), 5.29–4.98 (m, 2 H), 4.88 (dp, J = 17.8, 4.4 Hz, 1 H), 4.54 (dt, J = 27.6, 7.5 Hz, 1 H), 4.46–4.20 (m, 2 H), 3.90–3.66 (m, 2 H), 2.69–2.38 (m, 1 H), 2.21 (dq, J = 12.9, 6.3 Hz, 1 H).

¹³C NMR (126 MHz, CDCl₃): δ = 171.27, 158.52, 154.12, 153.70, 143.57, 143.41, 143.22, 143.00, 140.78, 140.69, 134.86, 134.66, 128.07, 127.98, 127.87, 127.81, 127.63, 127.22, 127.20, 127.14, 126.55, 126.52, 124.61, 124.57, 124.54, 124.40, 119.48, 119.42, 115.07 (t, ¹ J _C–F = 262.5 Hz, CHF₂), 71.25 (t, J = 5.0 Hz) and 70.43 (t, J = 5.5 Hz) (CHO), 67.28, 66.67, 66.61, 57.26, 56.96, 52.91, 52.31, 51.89, 46.60, 36.92, 35.77.

MS (ES-API): m/z (%) = 494 (100) [M + 1]⁺.

Anal. Calcd for C₂₈H₂₅F₂NO₅: C, 68.15; H, 5.11; N, 2.84. Found: C, 68.19; H, 5.21; N, 2.75.

(2R,4R)-1-((9H-Fluoren-9-yl)methyl) 2-Benzyl 4-(Difluoromethoxy)pyrrolidine-1,2-dicarboxylate (3s)

Purified by flash chromatography (hexane/EtOAc, 4:1).

Yield: 20 g (43%); white solid; mp 42 °C.

¹H NMR (500 MHz, CDCl₃): δ = 7.77 (t, J = 8.1 Hz, 2 H), 7.66–7.48 (m, 2 H), 7.46–7.20 (m, 9 H), 6.24–5.72 (m, 1 H), 5.32–5.02 (m, 2 H), 4.84 (ddq, J = 25.0, 5.6, 2.8 Hz, 1 H), 4.70–4.02 (m, 4 H), 3.91–3.66 (m, 2 H), 2.59–2.33 (m, 2 H).

¹³C NMR (151 MHz, CDCl₃): δ = 171.00 and 170.87, 154.54 and 154.20, (144.09, 143.66 and 143.64), (141.34, 141.32, 141.26 and 141.23), (135.58 and 135.41), (128.47, 128.42, 128.34 and 128.25), (127.75, 127.71, 127.65, 127.09, 127.07 and 127.03), (125.14, 125.01, 124.98 and 124.90), 119.99 and 119.94, 115.35 (t, ¹ J _C–F = 263.0 Hz, CHF₂), 71.79 (t, J = 5.2 Hz) and 70.86 (t, J = 5.3 Hz) (CHO), 67.73 and 67.57, 67.08 and 67.05, 57.74 and 57.48, 52.93 and 52.51, 47.17, 37.36 and 36.27.

¹⁹F NMR (376 MHz, CDCl₃): δ = –83.28, –83.70, –83.73, –83.76, –83.83, –84.26.

MS (ES-API): m/z (%) = 494 (100) [M + 1]⁺.

Anal. Calcd for C₂₈H₂₅F₂NO₅: C, 68.15; H, 5.11; N, 2.84. Found: C, 68.31; H, 5.02; N, 2.71.

(2S,4S)-1-((9H-Fluoren-9-yl)methyl) 2-Benzyl 4-(Difluoromethoxy)pyrrolidine-1,2-dicarboxylate (3t)

Purified by flash chromatography (hexane/EtOAc, 4:1).

Yield: 22 g (40.8%); white solid; mp 83 °C.

¹H NMR (400 MHz, CDCl₃): δ = 7.75 (t, J = 7.5 Hz, 2 H), 7.67–7.45 (m, 2 H), 7.45–7.20 (m, 8 H), 5.97 (td, J = 73.0, 17.5 Hz, 1 H), 5.33–4.96 (m, 2 H), 4.92–4.72 (m, 1 H), 4.67–3.97 (m, 4 H), 3.94–3.62 (m, 2 H), 2.41 (td, J = 14.2, 9.5 Hz, 2 H).

¹³C NMR (101 MHz, CDCl₃): δ = 171.02 and 170.89, 154.56 and 154.22, 144.08, 143.65, 141.34, 135.56, 135.40, 128.48, 128.44, 128.37, 128.27, 127.76, 127.72, 127.66, 127.08, 125.15, 125.00, 124.91, 120.00, 119.96, 115.34 (t, ¹ J _C–F = 263.0 Hz, CHF₂), 70.84, 67.74, 67.58, 67.11, 67.07, 57.74, 57.49, 52.95, 52.54, 47.17, 37.39, 36.30.

¹⁹F NMR (376 MHz, CDCl₃): δ = –83.30, –83.33, –83.72, –83.75, –83.79, –83.86, –84.21, –84.28.

MS (ES-API): m/z (%) = 494 (100) [M + 1]⁺.

Anal. Calcd for C₂₈H₂₅F₂NO₅: C, 68.15; H, 5.11; N, 2.84. Found: C, 68.03; H, 5.08; N, 2.96.

(2S,4R)-1-((9H-Fluoren-9-yl)methyl) 2-Benzyl 4-(Difluoromethoxy)pyrrolidine-1,2-dicarboxylate (3u)

Purified by flash chromatography (hexane/EtOAc, 5:1).

Yield: 21.8 g (39%); light-yellow thick oil.

¹H NMR (500 MHz, CDCl₃): δ = 7.87–7.66 (m, 2 H), 7.65–7.45 (m, 2 H), 7.45–7.20 (m, 9 H), 6.23 (td, J = 73.2, 8.7 Hz, 1 H), 5.35–4.99 (m, 2 H), 4.89 (dt, J = 22.6, 4.2 Hz, 1 H), 4.55 (dt, J = 35.1, 7.5 Hz, 1 H), 4.45–4.20 (m, 3 H), 3.91–3.64 (m, 2 H), 2.62–2.42 (m, 1 H), 2.31–2.07 (m, 1 H).

¹³C NMR (126 MHz, CDCl₃): δ = 171.27, 154.11, 153.68, 143.56, 143.40, 143.21, 142.98, 140.77, 140.69, 134.85, 134.65, 128.06, 127.98, 127.86, 127.81, 127.62, 127.22, 127.20, 127.13, 126.55, 126.51, 124.61, 124.57, 124.53, 124.40, 119.48, 119.41, 115.07 (t, J = 262.4 Hz, CHF₂), 71.24, 70.42, 67.28, 67.26, 66.67, 66.60, 57.25, 56.95, 52.31, 51.89, 48.94, 36.92, 35.77.

¹⁹F NMR (376 MHz, CDCl₃): δ = –83.03, –83.44, –83.56, –83.98.

MS (ES-API): m/z (%) = 494 (100) [M + 1]⁺.

Anal. Calcd for C₂₈H₂₅F₂NO₅: C, 68.15; H, 5.11; N, 2.84. Found: C, 68.24; H, 5.27; N, 2.88.

Synthesis of Compounds 4a, 4b, 4d–i, and 4m; General Procedure for Boc Deprotection

Acetyl chloride (2 equiv) was added dropwise to cooled MeOH (3 mL/mmol) at 0 °C, and the resulting solution was stirred at 0 °C for 20 minutes. A solution of the appropriate difluoromethoxy compound in MeOH (0.5 mL/mmol) was then added dropwise to the previous solution at 0 °C. The resulting solution was allowed to warm to r.t. and stirred overnight.

The reaction mixture was concentrated in vacuo at 40 °C, and Et₂O was added to the residue. The resulting suspension was filtered, and the filter cake was washed with Et₂O. The filter cake was dried in vacuo to obtain the target product.

3-((Difluoromethoxy)methyl)azetidine (4a)

The crude product was treated with 20% NaOH and extracted with Et₂O. The organic layer was dried over Na₂SO₄, filtered, and concentrated in vacuo.

The crude product was purified by distillation (46 °C, 20 mmHg).

Yield: 31 g (63.8%); colorless liquid.

¹H NMR (500 MHz, CDCl₃): δ = 6.22 (t, J = 74.7 Hz, 1 H), 4.00 (d, J = 6.5 Hz, 2 H), 3.71 (t, J = 8.0 Hz, 2 H), 3.46 (dd, J = 8.1, 6.2 Hz, 2 H), 3.00 (p, J = 7.1 Hz, 1 H), 2.17 (s, 2 H).

¹³C NMR (101 MHz, CDCl₃): δ = 115.89 (t, ¹ J _C–F = 260.0 Hz, CHF₂), 65.06 (t, J = 5.2 Hz, CH₂O), 49.11 (2 × CH₂), 33.69.

¹⁹F NMR (376 MHz, CDCl₃): δ = –84.56.

MS (ES-API): m/z (%) = 138 (100) [M + 1]⁺.

Anal. Calcd for C₅H₉F₂NO: C, 43.79; H, 6.62; N, 10.21. Found: C, 43.73; H, 6.74; N, 10.12.

2-((Difluoromethoxy)methyl)azetidine (4b)

The crude product was treated with 20% NaOH and extracted with Et₂O. The organic layer was dried over Na₂SO₄, filtered, and concentrated in vacuo.

The crude product was purified by distillation (44 °C, 20 mmHg).

Yield: 18.5 g (74.4%); colorless liquid.

¹H NMR (600 MHz, DMSO-d ₆): δ = 6.65 (t, J = 76.5 Hz, 1 H), 3.91 (ddd, J = 13.3, 7.4, 5.7 Hz, 1 H), 3.83–3.68 (m, 2 H), 3.44 (td, J = 8.2, 6.9 Hz, 1 H), 3.14 (ddd, J = 8.8, 6.9, 4.2 Hz, 1 H), 2.16 (dtd, J = 10.9, 8.2, 4.3 Hz, 1 H), 1.96 (dq, J = 11.0, 8.1 Hz, 1 H).

¹³C NMR (151 MHz, DMSO-d ₆): δ = 117.59 (t, ¹ J _C–F = 255.9 Hz, CHF₂), 69.59 (t, J = 3.8 Hz, CH₂-O), 56.48, 43.29, 23.65.

¹⁹F NMR (376 MHz, DMSO-d ₆): δ = –82.28.

MS (ES-API): m/z (%) = 138 (100) [M + 1]⁺.

Anal. Calcd for C₅H₉F₂NO: C, 43.79; H, 6.62; N, 10.21. Found: C, 43.88; H, 6.51; N, 10.34.

(S)-2-((Difluoromethoxy)methyl)pyrrolidine (4d)

Yield (HCl salt): 28.17 g (80.1%); yellow powder; mp 85 °C (decomp.); [α]_D +16.84 (MeOH, c = 26.7 mmol/L).

¹H NMR (400 MHz, DMSO-d ₆): δ = 9.75 (s, 1 H) and 9.32 (s, 1 H), 6.78 (t, J = 75.5 Hz, 1 H), 4.23–3.99 (m, 2 H), 3.72 (p, J = 7.4 Hz, 1 H), 3.16 (td, J = 7.4, 3.5 Hz, 2 H), 2.04 (ddd, J = 12.4, 8.1, 4.5 Hz, 1 H), 1.99–1.77 (m, 2 H), 1.62 (dq, J = 12.4, 8.3 Hz, 1 H).

¹³C NMR (126 MHz, DMSO-d ₆): δ = 116.66 (t, ¹ J _C–F = 258.1 Hz, CHF₂), 63.31, 57.51, 44.82, 26.19, 23.02.

¹⁹F NMR (376 MHz, DMSO-d ₆): δ = –83.36, –83.79, –83.94, –84.37.

MS (ES-API): m/z (%) = 152 (100) [M + 1]⁺.

Anal. Calcd for C₆H₁₁F₂NO·HCl: C, 38.41; H, 6.45; N, 7.47. Found: C, 38.27; H, 6.34; N, 7.59.

(R)-2-((Difluoromethoxy)methyl)pyrrolidine (4e)

Yield (HCl salt): 33.19 g (94.3%); white powder; mp 84 °C (decomp.); [α]_D –17.76 (MeOH, c = 26.7 mmol/L).

¹H NMR (400 MHz, DMSO-d ₆): δ = 9.75 (s, 1 H), 9.30 (s, 1 H), 6.78 (t, J = 75.5 Hz, 1 H), 4.08 (dd, J = 6.2, 3.3 Hz, 2 H), 3.73 (s, 1 H), 3.23–3.05 (m, 2 H), 2.04 (qd, J = 7.8, 3.7 Hz, 1 H), 1.89 (ddd, J = 24.5, 13.5, 5.8 Hz, 2 H), 1.76–1.51 (m, 1 H).

¹³C NMR (126 MHz, DMSO-d ₆): δ = 116.66 (t, ¹ J _C–F = 258.1 Hz, CHF₂), 63.32 (t, J = 4.6 Hz, CH₂O), 57.49, 44.80, 26.20, 23.02.

¹⁹F NMR (376 MHz, DMSO-d ₆): δ = –83.36, –83.79, –83.94, –84.37.

MS (ES-API): m/z (%) = 152 (100) [M + 1]⁺.

Anal. Calcd for C₆H₁₁F₂NO·HCl: C, 38.41; H, 6.45; N, 7.47. Found: C, 38.35; H, 6.57; N, 7.59.

(1R,3R,5S)-3-(Difluoromethoxy)-8-azabicyclo[3.2.1]octane (4f)

The crude product was treated with 20% NaOH and extracted with Et₂O. The organic layer was dried over Na₂SO₄, filtered, and concentrated in vacuo.

The crude product was purified by distillation (50 °C, 0.5 mmHg).

Yield: 28 g (68.6%); colorless oil.

¹H NMR (400 MHz, CDCl₃): δ = 6.15 (t, J = 75.5 Hz, 1 H), 4.38 (t, J = 5.1 Hz, 1 H), 3.48 (p, J = 3.2 Hz, 2 H), 2.10 (t, J = 7.1 Hz, 2 H), 1.99 (dt, J = 15.1, 4.4 Hz, 2 H), 1.92–1.79 (m, 3 H), 1.79–1.65 (m, 2 H).

¹³C NMR (126 MHz, CDCl₃): δ = 116.19 (t, ¹ J _C–F = 257.1 Hz, CHF₂), 69.50 (t, ³ J _C–F = 3.9 Hz, CHO), 52.84 (2 × CHN), 37.63 (2 × CH₂), 28.55 (2 × CH₂).

¹⁹F NMR (376 MHz, CDCl₃): δ = –81.81.

MS (ES-API): m/z (%) = 178 (100) [M + 1]⁺.

Anal. Calcd for C₈H₁₃F₂NO: C, 54.23; H, 7.40; N, 7.90. Found: C, 54.31; H, 7.59; N, 7.97.

(R)-3-(Difluoromethoxy)piperidine (4g)

The crude product was treated with 20% NaOH and extracted with Et₂O. The organic layer was dried over Na₂SO₄, filtered, and concentrated in vacuo.

The crude product was purified by distillation (81 °C, 20 mmHg).

Yield: 22.23 g (70.7%); colorless oil; [α]_D +13.96 (MeOH, c = 33.1 mmol/L).

¹H NMR (400 MHz, CDCl₃): δ = 6.26 (t, J = 75.2 Hz, 1 H), 4.16 (tt, J = 7.4, 3.7 Hz, 1 H), 3.09 (dd, J = 12.8, 3.5 Hz, 1 H), 2.91–2.65 (m, 3 H), 2.03–1.86 (m, 3 H), 1.85–1.63 (m, 2 H), 1.51 (ddq, J = 13.1, 8.8, 4.2 Hz, 1 H).

¹³C NMR (125 MHz, CDCl₃): δ = 115.66 (t, J = 259.1 Hz, CHF₂), 70.17 (t, J = 3.6 Hz, CH-O), 50.81, 45.30, 30.47, 23.45.

¹⁹F NMR (376 MHz, CDCl₃): δ = –81.33.

MS (ES-API): m/z (%) = 152 (100) [M + 1]⁺.

Anal. Calcd for C₆H₁₁F₂NO: C, 47.68; H, 7.34; N, 9.27. Found: C, 47.81; H, 7.42; N, 9.21.

(S)-3-(Difluoromethoxy)piperidine (4h)

The crude product was treated with 20% NaOH and extracted with Et₂O. The organic layer was dried over Na₂SO₄, filtered, and concentrated in vacuo.

The crude product was purified by distillation (80 °C, 20 mmHg).

Yield: 18.66 g (67.5%); colorless oil; [α]_D –13.36 (MeOH, c = 33.1 mmol/L).

¹H NMR (500 MHz, CDCl₃): δ = 6.25 (t, J = 75.2 Hz, 1 H), 4.14 (tt, J = 7.5, 3.7 Hz, 1 H), 3.12–3.02 (m, 1 H), 2.90–2.64 (m, 3 H), 1.93 (ddt, J = 12.1, 7.7, 4.0 Hz, 1 H), 1.84 (s, 1 H), 1.77 (dtt, J = 13.8, 7.0, 3.7 Hz, 1 H), 1.68 (dtd, J = 12.7, 8.4, 4.0 Hz, 1 H), 1.48 (dtt, J = 12.7, 8.1, 3.9 Hz, 1 H).

¹³C NMR (101 MHz, CDCl₃): δ = 116.16 (t, J = 258.7 Hz, CHF₂), 70.65 (t, J = 3.3 Hz, CH-O), 51.11, 45.62, 30.83, 23.80.

¹⁹F NMR (376 MHz, CDCl₃): δ = –81.33.

MS (ES-API): m/z (%) = 152 (100) [M + 1]⁺.

Anal. Calcd for C₆H₁₁F₂NO: C, 47.68; H, 7.34; N, 9.27. Found: C, 47.74; H, 7.27; N, 9.17.

4-(Difluoromethoxy)piperidine (4i)

The crude product was treated with 20% NaOH and extracted with Et₂O. The organic layer was dried over Na₂SO₄, filtered, and concentrated in vacuo.

The crude product was purified by distillation (75 °C, 20 mmHg).

Yield: 34 g (82.6%); colorless oil.

¹H NMR (500 MHz, CDCl₃): δ = 6.19 (t, J = 75.4 Hz, 1 H), 4.16 (tt, J = 8.9, 4.1 Hz, 1 H), 3.03 (dt, J = 12.8, 4.5 Hz, 2 H), 2.61 (ddd, J = 12.8, 9.9, 3.0 Hz, 2 H), 1.94–1.82 (m, 2 H), 1.56 (tq, J = 9.3, 5.5, 4.7 Hz, 3 H).

¹³C NMR (151 MHz, CDCl₃): δ = 116.16 (t, J = 258.4 Hz, CHF₂), 72.06, 43.92 (2 × CH₂N), 33.53 (2 × CH₂).

¹⁹F NMR (376 MHz, CDCl₃): δ = –81.14, –81.18.

MS (ES-API): m/z (%) = 152 (100) [M + 1]⁺.

Anal. Calcd for C₆H₁₁F₂NO: C, 47.68; H, 7.34; N, 9.27. Found: C, 47.57; H, 7.44; N, 9.33.

(1R,3S,4S)-3-((Difluoromethoxy)methyl)-2-azabicyclo[2.2.1]heptane (4m)

Yield (HCl salt): 16.67 g (82.4%); white powder; mp 115 °C (decomp.).

¹H NMR (400 MHz, DMSO-d ₆): δ = 9.29 (s, 2 H), 6.76 (dd, J = 77.3, 74.8 Hz, 1 H), 4.06–3.78 (m, 3 H), 3.41 (dd, J = 9.0, 5.1 Hz, 1 H), 1.88–1.72 (m, 2 H), 1.72–1.59 (m, 2 H), 1.59–1.35 (m, 2 H).

¹³C NMR (151 MHz, DMSO-d ₆): δ = 119.02, 117.33, 117.31, 115.61, 64.00, 63.97, 61.52, 58.02, 40.52, 37.67, 35.02, 27.67, 27.54, 25.04.

¹⁹F NMR (376 MHz, DMSO-d ₆): δ = –83.04, –83.47, –83.89, –84.32.

MS (ES-API): m/z (%) = 178 (100) [M + 1]⁺.

Anal. Calcd for C₈H₁₃F₂NO·HCl: C, 44.97; H, 6.61; N, 6.56. Found: C, 44.83; H, 6.49; N, 6.50.

Synthesis of 4c and 4j–l; General Procedure for Cbz Deprotection (D)

Cbz protected compound was added to the suspension of freshly prepared Raney Ni (1 g per 1 g of compound) in MeOH (2 mL/mmol) and the resulting suspension was vigorously stirred overnight.

The catalyst was filtered off and the filtrate was concentrated in vacuo. The residue was re-dissolved in MeOH (2 mL/mmol) and 10% Pd/C (5 mol%) was added. The resulting mixture was degassed and backfilled with hydrogen three times and the resulting mixture was hydrogenated at 1 atm (balloon) overnight.

The catalyst was filtered off and the filtrate was concentrated in vacuo. The residue was dissolved in MTBE and the resulting solution was washed with 2N NaOH solution. The organic layer was dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was distilled in vacuo to obtain the appropriate product.

3-(Difluoromethoxy)-3-methylazetidine (4c)

Distilled at 39 °C (20 mmHg).

Yield: 10 g (53.9%); colorless oil.

¹H NMR (500 MHz, CDCl₃): δ = 6.26 (t, J = 75.5 Hz, 1 H), 3.89 (d, J = 8.6 Hz, 2 H), 3.50–3.37 (m, 2 H), 1.86 (s, 1 H), 1.68 (s, 3 H).

¹³C NMR (101 MHz, CDCl₃): δ = 115.57 (t, ¹ J _C–F = 255.3 Hz, CHF₂), 77.81 (t, ³ J _C–F = 1.9 Hz, C-O), 58.51 (2 × CH₂), 23.45 (CH₃).

¹⁹F NMR (376 MHz, CDCl₃): δ = –79.31.

MS (ES-API): m/z (%) = 138 (100) [M + 1]⁺.

Anal. Calcd for C₅H₉F₂NO: C, 43.79; H, 6.62; N, 10.21. Found: C, 43.59; H, 6.73; N, 10.24.

2-((Difluoromethoxy)methyl)piperidine (4j)

Distilled at 35 °C (1 mmHg).

Yield: 31.55 g (63.5%); colorless oil.

¹H NMR (500 MHz, CDCl₃): δ = 6.19 (t, J = 74.9 Hz, 1 H), 3.78 (dd, J = 9.7, 3.6 Hz, 1 H), 3.65 (dd, J = 9.7, 8.4 Hz, 1 H), 3.07 (ddt, J = 11.8, 4.1, 2.1 Hz, 1 H), 2.78 (ddt, J = 11.3, 8.3, 3.1 Hz, 1 H), 2.62 (td, J = 11.7, 2.8 Hz, 1 H), 1.89 (s, 1 H), 1.86–1.76 (m, 1 H), 1.67–1.51 (m, 2 H), 1.38 (dddd, J = 34.7, 16.4, 12.7, 8.9 Hz, 2 H), 1.14 (tdd, J = 12.4, 11.0, 3.9 Hz, 1 H).

¹³C NMR (101 MHz, CDCl₃): δ = 116.03 (t, ¹ J _C–F = 260.3 Hz, CHF₂), 68.09 (t, ³ J _C–F = 4.9 Hz, CH₂O), 55.35, 46.41, 28.40, 26.12, 24.19.

¹⁹F NMR (376 MHz, CDCl₃): δ = –83.96, –84.38, –84.54, –84.96.

MS (ES-API): m/z (%) = 166 (100) [M + 1]⁺.

Anal. Calcd for C₇H₁₃F₂NO: C, 50.90; H, 7.93; N, 8.48. Found: C, 50.73; H, 7.99; N, 8.43.

3-((Difluoromethoxy)methyl)piperidine (4k)

Distilled at 40 °C (1 mmHg).

Yield: 29.73 g (63.4%); colorless oil.

¹H NMR (400 MHz, CDCl₃): δ = 6.16 (t, J = 75.1 Hz, 1 H), 3.73–3.57 (m, 2 H), 3.10 (d, J = 11.9 Hz, 1 H), 2.98 (d, J = 12.1 Hz, 1 H), 2.54 (td, J = 11.7, 3.0 Hz, 1 H), 2.35 (dd, J = 12.0, 9.9 Hz, 1 H), 1.78 (q, J = 5.4, 4.4 Hz, 2 H), 1.65 (dt, J = 13.4, 3.5 Hz, 1 H), 1.57 (s, 1 H), 1.53–1.37 (m, 1 H), 1.20–1.04 (m, 1 H).

¹³C NMR (151 MHz, CDCl₃): δ = 115.99 (t, ¹ J _C–F = 259.9 Hz, CHF₂), 66.33 (t, ³ J _C–F = 5.2 Hz, CH₂O), 49.67, 46.86, 36.77, 27.57, 25.80.

¹⁹F NMR (376 MHz, CDCl₃): δ = –84.65, –84.66.

MS (ES-API): m/z (%) = 166 (100) [M + 1]⁺.

Anal. Calcd for C₇H₁₃F₂NO: C, 50.90; H, 7.93; N, 8.48. Found: C, 51.08; H, 8.12; N, 8.54.

4-((Difluoromethoxy)methyl)piperidine (4l)

Distilled at 39 °C (1 mmHg).

Yield: 32.2 g (77.8%); colorless oil.

¹H NMR (500 MHz, CDCl₃): δ = 6.13 (t, J = 75.2 Hz, 1 H), 3.60 (d, J = 6.2 Hz, 2 H), 3.03 (dt, J = 12.4, 3.1 Hz, 2 H), 2.55 (td, J = 12.2, 2.5 Hz, 2 H), 1.67 (ddt, J = 15.5, 12.3, 3.0 Hz, 3 H), 1.58 (s, 1 H), 1.22–1.03 (m, 2 H).

¹³C NMR (151 MHz, CDCl₃): δ = 116.04 (t, ¹ J _C–F = 259.7 Hz, CHF₂), 68.25 (t, ³ J _C–F = 5.0 Hz, CH₂O), 46.09 (2 × CH₂N), 36.09, 46.09 (CH₂), 29.83, 46.09 (2 × CH₂).

¹⁹F NMR (376 MHz, CDCl₃): δ = –84.47.

MS (ES-API): m/z (%) = 166 (100) [M + 1]⁺.

Anal. Calcd for C₇H₁₃F₂NO: C, 50.90; H, 7.93; N, 8.48. Found: C, 50.84; H, 7.81; N, 8.37.

Synthesis of Compounds 4n–p; General Procedure for LiOH Hydrolysis

The starting compound was dissolved in THF (2 mL/mmol) and the solution of lithium hydroxide monohydrate (1.5 equiv) in water (2 mL/mmol) was added in one portion. The resulting mixture was stirred overnight.

The reaction mixture was diluted with MTBE and the aqueous layer was separated. The organic layer was extracted twice with water and then discarded. The combined aqueous layers were washed with MTBE twice and then acidified with an equimolar amount of sodium hydrosulfate. The resulting mixture was extracted twice with DCM. Combined DCM layers were dried over Na₂SO₄, filtered, and concentrated in vacuo to obtain the appropriate compound.

(2R,4R)-1-(tert-Butoxycarbonyl)-4-(difluoromethoxy)pyrrolidine-2-carboxylic Acid (4n)

Yield: 29 g (83.2%); white powder; mp 72 °C; [α]_D +48.22 (MeOH, c = 17.8 mmol/L).

¹H NMR (500 MHz, DMSO-d ₆): δ = 12.68–12.38 (m, 1 H), 6.67 (td, J = 75.4, 3.5 Hz, 1 H), 4.75 (ddp, J = 11.9, 5.8, 2.9 Hz, 1 H), 4.19 (ddd, J = 13.2, 9.5, 3.3 Hz, 1 H), 3.64 (ddd, J = 15.0, 11.9, 5.7 Hz, 1 H), 3.32 (dd, J = 12.0, 3.2 Hz, 1 H), 2.57–2.50 (m, 1 H), 2.06 (tt, J = 9.5, 4.1 Hz, 1 H), 1.36 (d, J = 25.7 Hz, 9 H).

¹³C NMR (151 MHz, DMSO-d ₆): δ = 173.34 and 173.01, 153.63 and 153.40, 117.30 (t, ¹ J _C–F = 256.0 Hz, CHF₂), 79.53 and 79.42, 74.31 and 73.30, 57.50 and 57.26, 52.65 and 52.24, 36.57 and 35.81, 28.48 and 28.31 (3 × CH₃).

¹⁹F NMR (376 MHz, DMSO-d ₆): δ = –81.74 and –81.78.

MS (ES-API): m/z (%) = 280 (100) [M – 1]⁺.

Anal. Calcd for C₁₁H₁₇F₂NO₅: C, 46.98; H, 6.09; N, 4.98. Found: C, 47.13; H, 6.15; N, 4.90.

(2S,4S)-1-(tert-Butoxycarbonyl)-4-(difluoromethoxy)pyrrolidine-2-carboxylic Acid (4o)

Yield: 21.1 g (88.6%); white solid; mp 71 °C; [α]_D –48.64 (MeOH, c = 17.8 mmol/L).

¹H NMR (500 MHz, DMSO-d ₆): δ = 12.56 (s, 1 H), 6.68 (td, J = 75.4, 3.2 Hz, 1 H), 4.75 (ddt, J = 9.0, 5.9, 2.8 Hz, 1 H), 4.19 (ddd, J = 13.2, 9.5, 3.3 Hz, 1 H), 3.64 (ddd, J = 17.2, 12.0, 5.7 Hz, 1 H), 2.60–2.50 (m, 1 H), 2.05 (tt, J = 9.7, 4.4 Hz, 1 H), 1.36 (d, J = 26.1 Hz, 9 H).

¹³C NMR (101 MHz, CDCl₃): δ = 177.11 and 175.37, 155.14 and 153.68, 115.46 (t, ¹ J _C–F = 262.5 Hz, CHF₂), 81.48 and 80.94, 71.63 and 70.90, 57.27, 53.42, 52.85 and 52.05, 36.89 and 35.46, 28.29 and 28.16 (3 × CH₃).

¹⁹F NMR (376 MHz, DMSO-d ₆): δ = –81.69 and –81.74.

MS (ES-API): m/z (%) = 280 (100) [M – 1]⁺.

Anal. Calcd for C₁₁H₁₇F₂NO₅: C, 46.98; H, 6.09; N, 4.98. Found: C, 47.04; H, 6.00; N, 4.75.

(2R,4S)-1-(tert-Butoxycarbonyl)-4-(difluoromethoxy)pyrrolidine-2-carboxylic Acid (4p)

Yield: 9.79 g (85.6%); white powder; mp 87 °C; [α]_D +38.38 (MeOH, c = 17.8 mmol/L).

¹H NMR (500 MHz, DMSO-d ₆): δ = 12.73 (s, 1 H), 6.74 (t, J = 75.4 Hz, 1 H), 4.78 (dt, J = 4.6, 2.2 Hz, 1 H), 4.12 (dt, J = 10.2, 7.8 Hz, 1 H), 3.63–3.39 (m, 2 H), 2.43–2.28 (m, 1 H), 2.10 (tdd, J = 13.8, 7.6, 5.1 Hz, 1 H), 1.35 (d, J = 22.1 Hz, 9 H).

¹³C NMR (151 MHz, DMSO-d ₆): δ = 174.09 and 173.63, 153.88 and 153.40, 117.43 (t, ¹ J _C–F = 255.9 Hz, CHF₂), 79.78, 74.37 and 73.78, 57.68 and 57.40, 52.61 and 52.34, 36.68 and 35.88, 28.46 and 28.28 (3 × CH₃).

¹⁹F NMR (376 MHz, DMSO-d ₆): δ = –81.61 (d, J = 12.2 Hz).

MS (ES-API): m/z (%) = 280 (100) [M – 1]⁺.

Anal. Calcd for C₁₁H₁₇F₂NO₅: C, 46.98; H, 6.09; N, 4.98. Found: C, 46.88; H, 5.94; N, 5.07.

(2S,4R)-1-(tert-Butoxycarbonyl)-4-(difluoromethoxy)pyrrolidine-2-carboxylic Acid (4q) [21]

Yield: 9.79 g (86%); white powder; mp 87 °C.

Synthesis of 4r–u; General Procedure for Benzyl Deprotection

The corresponding compound 3r–u was dissolved in MeOH (15 mL/mmol) and added to the suspension of freshly prepared Raney Ni (1 g per 1 g of compound) in MeOH (5 mL/mmol) and the resulting suspension was vigorously stirred overnight.

The catalyst was filtered off and the filtrate was concentrated in vacuo. The residue was re-dissolved in MeOH (15 mL/mmol) and 10% Pd/C (5 mol%) was added. The resulting mixture was degassed and backfilled with hydrogen three times and the resulting mixture was hydrogenated at 1 atm (balloon) overnight.

The catalyst was filtered off and the filtrate was concentrated in vacuo. The residue was dissolved in aq. sodium bicarbonate solution and the resulting solution was washed twice with DCM. The aqueous layer was acidified with an equimolar amount of sodium hydrosulfate. The resulting mixture was extracted twice with DCM. The combined DCM layers were dried over Na₂SO₄, filtered, and concentrated in vacuo to obtain the appropriate compound.

(2R,4S)-1-(((9H-Fluoren-9-yl)methoxy)carbonyl)-4-(difluoromethoxy)pyrrolidine-2-carboxylic Acid (4r)

Yield: 8.3 g (81%); beige solid; mp 63 °C; [α]_D +39.01 (EtOH, c = 24.8 mmol/L).

¹H NMR (500 MHz, CDCl₃): δ = 7.75 (dd, J = 22.8, 7.6 Hz, 2 H), 7.55 (q, J = 11.3, 9.4 Hz, 2 H), 7.40 (q, J = 12.2, 9.8 Hz, 2 H), 7.34 (d, J = 12.0 Hz, 1 H), 6.23 (td, J = 73.0, 15.4 Hz, 1 H), 4.87 (d, J = 21.7 Hz, 1 H), 4.61–4.10 (m, 4 H), 3.71 (qd, J = 11.9, 10.2, 3.8 Hz, 2 H), 2.57–2.18 (m, 2 H).

¹³C NMR (126 MHz, CDCl₃): δ = 174.71, 155.17, 153.73, 143.10, 140.79, 127.30, 127.16, 126.60, 124.47, 124.28, 119.53, 119.44, 115.04, 70.96, 67.70, 67.24, 57.19, 56.47, 52.20, 51.93, 46.61, 46.53, 36.79, 35.22.

¹⁹F NMR (376 MHz, CDCl₃): δ = –83.47, –83.53, –83.63.

MS (ES-API): m/z (%) = 404 (100) [M + 1]⁺.

Anal. Calcd for C₂₁H₁₉F₂NO₅: C, 62.53; H, 4.75; N, 3.47. Found: C, 62.44; H, 4.73; N, 3.36.

(2R,4R)-1-(((9H-Fluoren-9-yl)methoxy)carbonyl)-4-(difluoromethoxy)pyrrolidine-2-carboxylic Acid (4s)

Yield: 13.54 g (81%); white solid; mp 74 °C; [α]_D +37.89 (EtOH, c = 12.4 mmol/L).

¹H NMR (500 MHz, DMSO-d ₆): δ = 12.75 (s, 1 H), 7.87 (t, J = 7.8 Hz, 2 H), 7.64 (dt, J = 12.1, 4.4 Hz, 2 H), 7.50–7.17 (m, 4 H), 6.71 (t, J = 75.3 Hz, 1 H), 4.82 (d, J = 5.7 Hz, 1 H), 4.69–4.05 (m, 5 H), 3.72 (dt, J = 11.6, 5.7 Hz, 1 H), 3.45 (d, J = 12.0 Hz, 1 H), 2.58 (ddd, J = 14.5, 9.7, 5.6 Hz, 1 H), 2.18 (dd, J = 45.2, 14.0 Hz, 1 H).

¹³C NMR (151 MHz, DMSO-d ₆): δ = 173.11, 172.71, 154.23, 154.18, 144.25, 144.12, 141.19, 141.17, 141.10, 141.08, 128.14, 127.58, 125.72, 125.63, 125.58, 120.59, 120.56, 120.51, 117.37 (t, ¹ J _C–F = 255.9 Hz, CHF₂), 74.53, 73.67, 67.49, 67.23, 57.78, 57.52, 53.16, 52.54, 49.04, 47.11, 47.01, 36.93, 35.84.

¹⁹F NMR (376 MHz, DMSO-d ₆): δ = –81.63, –81.66.

MS (ES-API): m/z (%) = 404 (100) [M + 1]⁺.

Anal. Calcd for C₂₁H₁₉F₂NO₅: C, 62.53; H, 4.75; N, 3.47. Found: C, 62.71; H, 4.84; N, 3.62.

(2S,4S)-1-(((9H-Fluoren-9-yl)methoxy)carbonyl)-4-(difluoromethoxy)pyrrolidine-2-carboxylic Acid (4t)

Yield: 15 g (83%); white powder; mp 75 °C; [α]_D –37.32 (EtOH, c = 12.4 mmol/L).

¹H NMR (500 MHz, DMSO-d ₆): δ = 12.72 (d, J = 74.2 Hz, 1 H), 7.88 (t, J = 7.9 Hz, 2 H), 7.64 (ddd, J = 15.3, 7.5, 3.5 Hz, 2 H), 7.50–7.20 (m, 5 H), 6.71 (t, J = 75.3 Hz, 1 H), 4.81 (dp, J = 5.7, 2.7 Hz, 1 H), 4.52–4.04 (m, 5 H), 3.71 (dt, J = 11.5, 5.7 Hz, 1 H), 3.43 (d, J = 12.0 Hz, 1 H), 2.58 (s, 1 H), 2.22–2.04 (m, 1 H).

¹³C NMR (151 MHz, CDCl₃): δ = 176.05, 174.85, 155.35, 143.77, 143.51, 141.30, 127.79, 127.68, 127.10, 126.89, 125.03, 124.94, 123.98, 119.99, 115.38 (t, ¹ J _C–F = 262.9 Hz, CHF₂), 71.49, 70.84, 68.03, 67.68, 57.65, 57.01, 52.88, 52.66, 47.13, 37.17, 35.64.

¹⁹F NMR (376 MHz, DMSO-d ₆): δ = –81.66 (d, J = 10.6 Hz).

MS (ES-API): m/z (%) = 404 (100) [M + 1]⁺.

Anal. Calcd for C₂₁H₁₉F₂NO₅: C, 62.53; H, 4.75; N, 3.47. Found: C, 62.79; H, 4.63; N, 3.39.

(2S,4R)-1-(((9H-Fluoren-9-yl)methoxy)carbonyl)-4-(difluoromethoxy)pyrrolidine-2-carboxylic Acid (4u)

Yield: 15 g (84%); white powder; mp 65 °C; [α]_D –38.26 (EtOH, c = 24.8 mmol/L).

¹H NMR (500 MHz, CDCl₃): δ = 7.75 (dd, J = 24.2, 7.5 Hz, 2 H), 7.55 (q, J = 11.9, 9.8 Hz, 2 H), 7.46–7.28 (m, 4 H), 6.54–6.01 (m, 1 H), 4.87 (dt, J = 23.3, 4.3 Hz, 1 H), 4.63–4.32 (m, 3 H), 4.21 (dt, J = 61.2, 6.8 Hz, 1 H), 3.72 (ddd, J = 16.6, 11.6, 6.2 Hz, 2 H), 2.64–2.14 (m, 2 H).

¹³C NMR (126 MHz, CDCl₃): δ = 174.71, 155.17, 153.73, 143.10, 140.79, 127.30, 127.16, 126.60, 124.47, 124.28, 119.53, 119.44, 115.04, 70.96, 67.70, 67.24, 57.19, 56.47, 52.20, 51.93, 46.61, 46.53, 36.79, 35.22.

¹⁹F NMR (376 MHz, CDCl₃): δ = –83.47, –83.52, –83.62.

MS (ES-API): m/z (%) = 404 (100) [M + 1]⁺.

Anal. Calcd for C₂₁H₁₉F₂NO₅: C, 62.53; H, 4.75; N, 3.47. Found: C, 62.62; H, 4.81; N, 3.54.

(2S,4R)-1-tert-Butyl 2-(Chloromethyl) 4-(Difluoromethoxy)pyrrolidine-1,2-dicarboxylate (5q)

Sodium bicarbonate (22.2 g, 264.5 mmol, 4 equiv) was suspended in water (150 mL) and tetrabutylammonium sulfate (2.24 g, 6.6 mmol, 0.1 equiv) was added followed by the addition of the solution compound 4q (18.6 g, 66.1 mmol) in DCM (150 mL). The resulting mixture was stirred for 10 minutes and then cooled to 0 °C in an ice bath. The solution of chloromethyl sulfochloridate (13.1 g, 79.4 mmol, 1.2 equiv) in DCM (10 mL) was added dropwise at 0 °C. When the addition was complete, the reaction mixture was stirred at 0 °C for 30 minutes. Then the bath was removed, and the reaction mixture was stirred at r.t. for 90 minutes.

The organic layer was separated, and the aqueous layer was extracted with DCM (2 × 100 mL). The combined organic layers were washed with water (3 × 150 mL), dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (hexane/EtOAc, 19:1) to give compound 5q.

Yield: 10.57 g (48.5%); colorless oil; [α]_D –72.5 (MeOH, c = 15.2 mmol/L).

¹H NMR (500 MHz, CDCl₃): δ = 6.23 (t, J = 73.2 Hz, 1 H), 5.96–5.53 (m, 2 H), 4.87 (dt, J = 8.8, 4.6 Hz, 1 H), 4.45 (dt, J = 23.4, 7.7 Hz, 1 H), 3.79–3.54 (m, 2 H), 2.50 (ddd, J = 23.9, 11.3, 7.3 Hz, 1 H), 2.20 (ddd, J = 13.2, 7.3, 5.3 Hz, 1 H), 1.44 (d, J = 17.9 Hz, 8 H).

¹³C NMR (126 MHz, CDCl₃): δ = 170.10, 169.89, 158.53, 153.54, 152.70, 117.13, 115.04, 112.95, 80.61, 80.40, 71.16, 70.47, 68.61, 68.43, 56.88, 56.60, 51.96, 51.70, 36.52, 35.37, 27.78, 27.66.

¹⁹F NMR (376 MHz, CDCl₃): δ = –83.04, –83.47, –83.62, –84.04.

MS (ES-API): m/z (%) = 228 (20) [M – 1 – Boc]⁺, 180 (35) [M – 1 – Boc – CH₂Cl]⁺.

Anal. Calcd for C₁₂H₁₈ClF₂NO₅: C, 43.71; H, 5.50; N, 4.25. Found: C, 43.55; H, 5.70; N, 4.34.

Referenzen

References
1 Fluorine in Pharmaceutical and Medicinal Chemistry. In From Biophysical Aspects to Clinical Application. Gouverneur V. Imperial College Press; London: 2012
2 Reddy VP. Organofluorine Compounds in Biology and Medicine. Elsevier; Amsterdam: 2015
3 Fluorine in Life Sciences: Pharmaceuticals, Medicinal Diagnostics, and Agrochemicals. In Progress in Fluorine Science Series, Vol. 4. Haufe G, Leroux FR. Academic Press; San Diego: 2019
4 Swallow S. Prog. Med. Chem. 2016; 54: 65
5 Meanwell NA. J. Med. Chem. 2018; 61: 5822
6 Inoue M, Sumii Y, Shibata N. ACS Omega 2020; 5: 10633
7 Mei H, Han J, White S, Graham DJ, Izawa K, Sato T, Fustero S, Meanwell NA, Soloshonok VA. Chem. Eur. J. 2020; 26: 11349
8 Han J, Remete AM, Dobson LS, Kiss L, Izawa K, Moriwaki H, Soloshonok VA, O’Hagan D. J. Fluorine Chem. 2020; 239: 109639
9 Pokhodylo N, Levchenko K, Obushak M. ChemistrySelect 2024; 9: e202302753
10 Müller K. Chimia 2014; 68: 356
11 Huchet QA, Trapp N, Kuhn B, Wagner B, Fischer H, Kratochwil NA, Carreira EM, Müller K. J. Fluorine Chem. 2017; 198: 34
12 Chen QY, Wu SW. J. Fluorine Chem. 1989; 44: 433
13 Dolbier WR, Wang F, Tang X, Thomoson CS, Wang L. J. Fluorine Chem. 2014; 160: 72
14 Liu GK, Li X, Qin WB, Peng XS, Wong HN. C, Zhang L, Zhang X. Chem. Commun. 2019; 55: 7446
15 Prakash GK. S, Zhang Z, Wang F, Ni C, Olah GA. J. Fluorine Chem. 2011; 132: 792
16 Kyasa S, Dussault PH. Org. Lett. 2014; 16: 5235
17 Newton JJ, Engüdar G, Brooke AJ, Nodwell MB, Horngren-Rhodes H, Martin RE, Schaffer P, Britton R, Friesen CM. Chem. Eur. J. 2023; 29: e202202862
18 Xie Q, Ni C, Zhang R, Li L, Rong J, Hu J. Angew. Chem. Int. Ed. 2017; 56: 3206
19 Zhang R, Ni C, Xie Q, Hu J. Tetrahedron 2020; 76: 131676
20 Loison A, Hanquet G, Toulgoat F, Billard T, Panossian A, Leroux FR. Eur. J. Org. Chem. 2023; 26: e202300695
21 Levchenko K, Datsenko OP, Serhiichuk O, Tolmachev A, Iaroshenko VO, Mykhailiuk PK. J. Org. Chem. 2016; 81: 5803
22 Evans GB, Furneaux RH, Greatrex B, Murkin AS, Schramm VL, Tyler PC. J. Med. Chem. 2008; 51: 948
23 Abreo MA, Lin N.-H, Garvey DS, Gunn DE, Hettinger A.-M, Wasicak JT, Pavlik PA, Martin YC, Donnelly-Roberts DL, Anderson DJ, Sullivan JP, Williams M, Arneric SP, Holladay MW. J. Med. Chem. 1996; 39: 817
24 Wu Z, Laffoon SD, Nguyen TT, McAlpin JD, Hull KL. Angew. Chem. Int. Ed. 2017; 56: 1371
25 Slaitas A, Yeheskiely E. Eur. J. Org. Chem. 2002; 2391
26 Napier SE, Bingham MJ, Dunbar NA. WO Patent 200763071 A1, 2007
27 Kovačková S, Dračínský M, Rejman D. Tetrahedron 2011; 67: 1485
28 Bradbury RH, Hennequin LF. A, Kettle JG. WO Patent 200526152, 2005
29 Barré B, Gonnard L, Campagne R, Reymond S, Marin J, Ciapetti P, Brellier M, Guérinot A, Cossy J. Org. Lett. 2014; 16: 6160
30 Sasmal PK, Ahmed S, Tehim A, Paradkar V. US Patent 2015368238, 2015
31 Rosen T, Chu DT. W, Lico IM, Fernandes PB, Marsh K, Shen L, Cepa VG, Pernet AG. J. Med. Chem. 1988; 31: 1598
32 Planken S, Cheng H, Collins MR, Spangler JE, Brooun A, Maderna A, Palmer C, Linton MA, Nagata A, Chen P. US Patent 2019233440, 2019
33 Dally RD, Shepherd TA, Bender DM, Garcia MI. R. WO Patent 2005108358, 2005
34 Sanchez-Sancho F, Herradon B. Tetrahedron: Asymmetry 1998; 9: 1951
35 Abreu AR, Costa I, Rosa C, Ferreira LM, Lourenco A, Santos PP. Tetrahedron 2005; 61: 11986
36 Zhu K, Yang J.-S. Tetrahedron 2016; 22: 3113
37 Agarkov A, Greenfield SJ, Ohishi T, Collibee SE, Gilbertson SR. J. Org. Chem. 2004; 69: 8077

Abbildungen

Scheme 1 Proposed synthetic strategy

Scheme 2 Synthesis of compounds 4a–l. The yields of the last stage and over the two steps of difluoromethylation and deprotection (blue in parentheses) are given.

Scheme 3 Synthesis of compounds 4m

Scheme 4 Synthesis of compounds 4n–q. The yields of the last stage and over the two steps of difluoromethylation and deprotection (blue in parentheses) are given.

Scheme 5 Synthesis of compounds 4r–u. The yields of the last stage and over the two steps of difluoromethylation and deprotection (blue in parentheses) are given.

Zusatzmaterial

Supporting Information